Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ardeshir Khademi-Kermanshahi

Neurology Safety Harbor, FL Medical Doctor

NPI 1861585903 CMS profile 129468

1840 Mease Dr, Suite 407B, Safety Harbor, FL 34695

Open in the dashboard

General payments

$3,097

140 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ardeshir Khademi-Kermanshahi of Safety Harbor, FL is reported in the CMS Open Payments database as having received $3,097 across 140 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $305 11
2024 General $427 14
2023 General $527 21
2022 General $484 24
2021 General $406 21
2020 General $399 21
2019 General $549 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ardeshir Khademi-Kermanshahi
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Ardeshir Khademi-Kermanshahi were reported at $305. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Ardeshir Khademi-Kermanshahi Neurology median Middle half National median
2019 $549 $474 $118–$2,177 $163
2020 $399 $367 $82–$2,309 $114
2021 $406 $438 $104–$2,547 $132
2022 $484 $442 $103–$2,388 $149
2023 $527 $464 $119–$2,312 $160
2024 $427 $468 $119–$2,323 $164
2025 $305 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $492 22 payments
  2. SK Life Science, Inc. $353 5 payments
  3. Neurocrine Biosciences, Inc. $278 14 payments
  4. UCB, Inc. $257 9 payments
  5. Novartis Pharmaceuticals Corporation $163 10 payments
  6. Sunovion Pharmaceuticals Inc. $147 11 payments
  7. Kyowa Kirin, Inc. $131 2 payments
  8. Allergan Inc. $121 7 payments
  9. Supernus Pharmaceuticals, Inc. $115 7 payments
  10. Lilly USA, LLC $108 5 payments
  11. Other $933 48 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,082 139 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $15 1 payment
Products named General payments · program years 2019–2025
  1. XCOPRI $346 4 payments
  2. QULIPTA $259 13 payments
  3. INGREZZA $217 11 payments
  4. UBRELVY $170 10 payments
  5. Briviact $166 5 payments
  6. DUOPA $147 3 payments
  7. NOURIANZ $131 2 payments
  8. Ongentys $109 6 payments
  9. EMGALITY $108 5 payments
  10. TROKENDI XR $89 5 payments
  11. Other $1,732 95 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 63 drugs

Part D claims

3,045

Median for Neurology: 833

Drug cost

$717,648

Median for Neurology: $202,670

Branded share of claims

20.6%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gammaplex Immun Glob G(Igg)/Gly/Iga 0-50 Brand 16 $415,494
Nurtec Odt Rimegepant Sulfate Brand 33 $45,943
Ubrelvy Ubrogepant Brand 22 $30,838
Emgality Pen Galcanezumab-Gnlm Brand 34 $30,276
Neupro Rotigotine Brand 16 $28,718
Xcopri Cenobamate Brand 23 $27,645
Botox Onabotulinumtoxina Brand 23 $26,477
Aimovig Autoinjector Erenumab-Aooe Brand 22 $19,780
Vimpat Lacosamide Brand 13 $13,794
Rivastigmine Generic 48 $10,903

The 10 drugs with the highest cost, of 63 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$359,436

Medicare's payments for the services billed

Medicare patients

1,073

Average age 77

Services billed

7,119

620 women, 453 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Ischemic heart disease 44%
Depression 42%
Chronic kidney disease 37%
Diabetes 30%
Alzheimer's or dementia 30%
Atrial fibrillation 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XCOPRI
  • SK Life Science, Inc. $125
$125 23 —
Briviact
  • UCB, Inc. $70
$70 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $68
$68 — —
UBRELVY
  • AbbVie, Inc. $31
$31 22 —
QULIPTA
  • AbbVie, Inc. $31
$31 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

140 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record